|
A customer contacted the ortho clinical diagnostics (ortho) technical solution center (tsc) to report lower and higher than expected vitros therapeutic drug monitoring (tdm) performance verifier (pv) quality control results were obtained when processing two different vitros carbamazepine (crbm) slide lots using a vitros xt 7600 integrated system.Vitros crbm slide lot 3916-0125-1727: vitros tdm pv i y1734 results of 7.95 and 7.84 ug/ml versus the baseline mean value of 4.82 ug/ml vitros tdm pv iii b1736 results of 8.88, >20, >20, >20 and >20 ug/ml versus the baseline mean value of 13.32 ug/ml vitros crbm slide lot 3916-0125-1782: vitros tdm pv iii b1736 results of 9.31, 18.31, 17.92, 17.63, 18.52, 18.87, 17.4, 18.1, 17.8, 17.9, 18.4 and 17.6 ug/ml versus the baseline mean value of 13.32 ug/ml biased results of the magnitude and direction observed may lead to inappropriate physician action if they were to occur undetected on patient samples.The higher and lower than expected results were obtained from non-patient quality control fluids.The customer made no allegation that patient results were affected or reported from the laboratory.There was no allegation of patient harm as a result of this event.This report is number three of six mdrs for this event.Six 3500a forms are being submitted for this event as six devices were involved.This report corresponds to ortho clinical diagnostics inc (ortho) complaint numbers (b)(4) and reportability assessment (b)(4).
|